Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

Axsome Therapeutics Inc Stock

Price
Target price
€146.10

€146.10

-1.480%
-2.2
-1.480%
-
 
02.04.26 / Tradegate WKN: A2AA7B / Name: Axsome / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Axsome Therapeutics Inc in the next few years
Wizard

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Axsome Therapeutics Inc is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Axsome

sharewise wants to provide you with the best news and tools for Axsome, so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now: https://g.foolcdn.com/editorial/images/859763/doctor-and-patient-in-a-hospital-room.jpg
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now

Summit Therapeutics (NASDAQ: SMMT) has grown in prominence over the past three years, moving from a small-cap biotech to a large-cap valuation, driven by regulatory progress for its leading

TheMotleyFool 
0 25.03.26
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain: https://cdn.content.foolcdn.com/images/1umn9qeh/production/ad04e80951d6de292a5f59f60fce986c74bc8b4f-1401x1251.png?rect=76,0,1251,1251&w=384&h=384&q=75&fit=crop&auto=format
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain

On February 17, 2026, Superstring Capital Management disclosed a new position in Axsome Therapeutics (NASDAQ:AXSM), acquiring 37,433 shares worth $6.84 million in the fourth quarter.

According to a

TheMotleyFool 
0 18.03.26
Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision: https://cdn.content.foolcdn.com/images/1umn9qeh/production/1a599f395be31e2f508c3aa7decb988f9ce983b7-1401x1251.png?rect=76,0,1251,1251&w=384&h=384&q=75&fit=crop&auto=format
Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision

Herriot Tabuteau, CEO of Axsome Therapeutics (NASDAQ:AXSM), exercised and immediately sold 32,410 common shares in an open-market transaction on February 2, 2026, as disclosed in the SEC Form 4

TheMotleyFool 
0 09.03.26
Got $10,000? Axsome Therapeutics Could Be a Mental‑Health Moonshot by 2036: https://g.foolcdn.com/editorial/images/854892/person-raising-two-fists-in-the-air.jpg
Got $10,000? Axsome Therapeutics Could Be a Mental‑Health Moonshot by 2036

Axsome Therapeutics (NASDAQ: AXSM) isn't one of the more famous or prominent biotech companies, but investors interested in the industry had better get to know this drugmaker. Not only has Axsome

TheMotleyFool 
0 22.02.26
Should You Buy Axsome Therapeutics Stock Before Feb. 23?: https://g.foolcdn.com/editorial/images/853988/a-group-of-scientists-looking-at-a-report.jpg
Should You Buy Axsome Therapeutics Stock Before Feb. 23?

Axsome Therapeutics (NASDAQ: AXSM) has been a red-hot stock to own over the past 12 months. During that stretch, it has soared by around 75%, dwarfing the performance of the S&P 500, which is up by

TheMotleyFool 
0 05.02.26
1 High-Flying Stock With More Upside Ahead: https://g.foolcdn.com/editorial/images/853215/pharmacist-talking-to-patient.jpg
1 High-Flying Stock With More Upside Ahead

Over the past five years, Axsome Therapeutics (NASDAQ: AXSM) has been on fire. The company has crushed the market in this period on the back of solid clinical and regulatory progress. At this point

TheMotleyFool 
0 03.02.26
2 Under-the-Radar Stocks to Buy Heading Into 2026
2 Under-the-Radar Stocks to Buy Heading Into 2026

Axsome Therapeutics (NASDAQ: AXSM) and Exelixis (NASDAQ: EXEL) are hardly the best-known players in the large biotech industry. Thankfully, they don't need to be so to have excellent prospects. Both

TheMotleyFool 
0 02.12.25